Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior therapy. We report the updated safety and efficacy results from the multicenter, open-label phase 2 registration trial of ibrutinib (median 26.7-month follow-u...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Wang, Michael L., Blum, Kristie A., Martin, Peter, Goy, Andre, Auer, Rebecca, Kahl, Brad S., Jurczak, Wojciech, Advani, Ranjana H., Romaguera, Jorge E., Williams, Michael E., Barrientos, Jacqueline C., Chmielowska, Ewa, Radford, John, Stilgenbauer, Stephan, Dreyling, Martin, Jedrzejczak, Wieslaw Wiktor, Johnson, Peter, Spurgeon, Stephen E., Zhang, Liang, Baher, Linda, Cheng, Mei, Lee, Dana, Beaupre, Darrin M., Rule, Simon
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2015
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4528064/
https://ncbi.nlm.nih.gov/pubmed/26059948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-635326
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker